Predictive factors of chemotherapy-induced oral mucositis in colorectal cancer: role of polymorphisms in genes mediating the inflammatory response
DOI:
https://doi.org/10.31877/on.2010.14.02Keywords:
Oral mucositis, genetic polymorphisms, colorectal cancer, chemotherapy, inflammationAbstract
From a consecutive series of colorectal cancer patients treated with chemotherapy (n=108), a case-control study was performed, to establish the role of genetic polymorphisms in genes modulating the inflammatory response in the evolution of oral mucositis (OM). However, other variables influencing the individual risk for oral mucositis were included for study. No differences are observed both in gender, mean age of participants, body mass index, diabetes mellitus, dental prosthesis, smoking, alcohol consumption and hematological data changes between cases and controls. Earlier OM was reported in a higher proportion of cases (35%) (vs 0% in controls, p≤0.001). The TNF-α -308A allele appeared to be associated with a decreased risk for oral mucositis onset (OR=0.266; 95%CI: 0.073-0.964) in colorectal cancer patients treated with chemotherapy. Further studies should be conducted as this may represent a risk marker for this important side-effect after chemotherapy, in a way that may enable to submit patients to preventive strategies and early diagnosis.
Downloads
References
Boyle, P., Langman, J.S., ABC of Colorectal Cancer: Epidemiology. BMJ 2000; 32:805-808.
Wolpin, B.M., Meyerhardt, J.A., et al., Adjuvant Treatment of Colorectal Cancer. CA A Cancer Journal for Clinicians 2007; 57:168-85.
Costa, C., Magalhães, H., et al., O Cancro e a Qualidade de vida – A Quimioterapia e outros Fármacos no combate ao Cancro. 1ª Edição,
Novartis Farma 2005. ISBN: 972-9119-94-5.
Fadda, G., Campus, G., et al., Risk factorsfor oral mucositisin paediatric oncology patientsreceiving alkylant chemotherapy. BMC Oral Health2006; 6(13): http://www.biomedcentral.com/1472-6831/6/13.
Pico, J.L., Avila-Garavito, A., et al., Mucositis: Its Occurence, Consequences, and Treatment in the Oncology Setting. The Oncologist
; 3:446-451.
Köstler, W.J., Hejna, M., et al., Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Optionsfor Prevention and
Treatment. CA Cancer J Clin 2001; 51(5):290-315.
Stone, R., Fliedner, M.C., et al., Management of oral mucositisin patients with cancer. European Journal of Oncology Nursing 2005; 9
Suppl 1:24-32.
Cheng, K.K., Oral mucositis, dysfunction, and distressin patients undergoing cancer therapy. Journal of Clinical Nursing 2007; 16(11):2114-21.
Peterson, D.E., Cariello Anna, Mucosal Damage: A Major Risk Factor for Severe Complications After Cytotoxic Therapy. Seminarsin Oncology 2004; 31(3):35-44.
Sonis, S.T., Elting, L.S., Perspectives on Cancer Therapy-Induced Mucosal Injury: Pathogenesis, Measurement, Epidemiology, and
Consequencesfor patients. Cancer Supplement 2004; 100(9):1995-2011.
Sonis, S.T., Pathobiology of Oral Mucositis: Novel insights and opportunities. J Support Oncol 2007; 5(9):3-11.
Zhang, X., Miao, X., et al., Identification of Functional Genetic Variants in Cyclooxygenase-2 and their Association with risk of Esophageal
Cancer. Gastroenterology 2005; 129:565-76.
Pereira, C.; Sousa, H.; Ferreira, P.; Fragoso, M.; Moreira-Dias, L.; Lopes C.; Medeiros, R.; Dinis-Ribeiro, M.; –765G >C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J. Gastroenterol.2006; 12:
-5478.
Kristiansen, O.P.; Nolsøe, R.L.; Larsen, L.; Gjesing, A.M.; Johannesen, J.; Larsen, Z.M.; Lykkesfeldt, A.E.; Karlsen, A.E.; Pociot, F.; Mandrup-Poulsen, T.; Association of a functional 17beta-estradiolsensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetesin
females. Hum. Mol. Genet. 2003; 12:1101-1110.
Whyte, M., Hubbard, R., et al., Increased risk of fibrosing alveolitis associated with Interleukin-1 receptor antagonist and tumor necrosis
factor-a gene polymorphisms. Am J RespCrit CareMed. 2000; 162:755-58.
Szczeklil,W., Sanak, M., et al., Functional effects and gender association of COX-2 gene polymorphism G-765Cin bronchial asthma. J Allergy Clin Immunol, 2004. 114(2):248-53.
Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G.; Mayer, R.J.; Benson, A.B.; Macdonald, J.S.; Fuchs, C.S.; Influence of body massindex on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98:484-495.
Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G.; Mayer, R.J.; Macdonald, J.S.; Benson, A.B.; Fuchs, C.S.; Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 2003; 21: 433-440.
Sloan, J.A.; Loprinzi, C.L.; Novotny, P.J.; Okuno, S.; Nair, S.; Barton, D.L.; Sex Differencesin Fluorouracil-Induced Stomatitis. J. Clin. Oncol.
; 18:412-420.
McCarthy, G.M.; Awde, J.D.; Ghandi, H.; Vincent, M.; Kocha, W.I.; Risk factors associated with mucositisin cancerpatientsreceiving
-fluorouracil. Oral Oncol. 1998; 34:484-490.
Vatay, A., Bene, L., et al., Relationship between the tumor necrosis factor alpha polymorphisms and the serum C-reactive protein levelsin
inflammatory bowel disease. Immunogenetics 2003; 55:247-52.
Baran, W., Szepietowski, J.C., et al., A -308 promoter polymorphism of tumor necrosisfactor alpha gene does not associate with the
susceptibility to psoriasis vulgaris. No difference either between psoriasistype I and type II patients. Acta DermatovenAPA 2006;
(3):113-118.
Hall, P.D.; Benko, H.; Hogan, K.R.; Stuart, R.K.; The influence ofserum tumor necrosisfactor-alpha and interleukin-6 concentrations on
nonhematologic toxicity and hematologic recovery in patients with acute myelogenousleukaemia. Exp Hematol. 1995; 23:1256-60.
Logan, R.M.; Stringer, A.M.; Bowen, J.M.; Gibson, R.J.; Sonis, S.T.; Keefe, D.M.; Serum levels of NFkappaB and pro-inflammatory cytokines
following administration of mucotoxic drugs. Cancer Biol. Ther. 2008; 7:1139-1145.
Lima, V.; Brito, G.A.; Cunha, F.Q.; Rebouças, C.G.; Falcão, B.A.; Augusto, R.F.; Souza, M.L.; Leitão, B.T.; Ribeiro, R.A.; Effects of the tumour
necrosisfactor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositisin hamsters. Eur. J. Oral. Sci. 2005;
:210-217.
Guimarães, A.L., Correia-Silva, J.F., et al., Investigation of functional gene polymorphismsIL-1beta, IL-6, IL-10 and TNF-alpha in individuals
with recurrent aphthousstomatitis. Arch Oral Biol. 2007; 52(3):268-72.
Galbraith, G.M., Hendley, T.M., et al., Polymorphic cytokine genotypes as markers of disease severity in adult periodontitis. J Clin Periodontol. 1999; 26(11):705-9.
Shapira, L., Stabholz, A., et al., Genetic Polymorphism of the tumor necrosisfactor(TNF)-a promoter region in families with localized early-onset periodontitis. J Periodontal Res. 2001; 36(3):183-6.
Zheng, M.H.; Qiu, L.X.; Xin, Y.N.; Pan, H.F.; Shi, K.Q.; Chen, Y.P.; Tumor necrosisfactor-alpha-308A allele may have a protective effect for
chronic hepatitis B virusinfection in Mongoloid populations, Int. J. Infect. Dis. 2008;12:S62.
D. Gambhir D; Lawrence, A.; Aggarwal, A.; Misra, R.; Mandal, S.K.; Naik, S.; Association of tumor necrosisfactor alpha and IL-10 promoter
polymorphisms with rheumatoid arthritisin North Indian population. Rheumatol. Int. 2009.
Lalla, R.V.; Pilbeam, C.C.; Walsh, S.J.; Sonis, S.T.; Keefe, D.M.; Peterson, D.E.; Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilotstudy. Support Care Cancer 2009.
Lopes, N.N.; Plapler, H.; Chavantes, M.C.; Lalla, R.V.; Yoshimura, E.M.; Alves, M.T.; Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositisin hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer
; 17:1409-1415.
Zhang, X.; Miao, X.; Tan, W.; Ning, B.; Liu, Z.; Hong, Y.; et al.; Identification of functional genetic variantsin cyclooxygenase-2 and
their association with risk of esophageal cancer. Gastroenterology 2005; 129:565-576.
Zhao, D.; Xu, D.; Zhang, X.; Wang, L.; Tan, W.; Guo, Y.; et al.; Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a
possible role of nucleophosmin. Gastroenterology 2009; 136:1659-1668.
Ho, Y.P.; Lin, Y.C.; Yang, Y.H.; Ho, K.Y.; Wu, Y.M.; Tsai, C.C.; Cyclooxygenase-2 Gene-765 single nucleotide polymorphism as a
protective factor against periodontitisin Taiwanese. J Clin Periodontol, 2008; 35.
Xie, C.J.; Xiao, L.M.; Fan, W.H.; Xuan, D.Y.; Zhang J.C.; Common single nucleotide polymorphismsin cyclooxygenase-2 and risk ofsevere
chronic periodontitisin a Chinese population. J. Clin. Periodontol. 2009; 36:198-203.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Catarina Rodrigues, Carina Pereira, Rui Medeiros, Mário Dinis-Ribeiro
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.